A single tube 10-color flow cytometry assay optimizes detection of minimal residual disease in chronic lymphocytic leukemia

被引:22
|
作者
Sartor, M. M. [1 ]
Gottlieb, D. J. [2 ]
机构
[1] Westmead Hosp, Flow Cytometry Unit, ICPMR, Westmead, NSW 2145, Australia
[2] Univ Sydney, Fac Med, Sydney, NSW 2006, Australia
关键词
chronic lymphocytic leukemia; minimal residual disease; multiparameter flow cytometry; STEM-CELL TRANSPLANTATION; CLL PATIENTS; RITUXIMAB; PCR; QUANTIFICATION; ALEMTUZUMAB; MODULATION; TRIAL; CD20;
D O I
10.1002/cyto.b.21067
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Levels of residual disease (RD) are an independent predictor of progression-free survival (PFS) and overall survival (OS) in patients treated for chronic lymphocytic leukemia (CLL). We modified the international standardized approach (ISA) to RD detection using flow cytometry by developing a single tube 10 color antibody assay. Method: A single tube incorporated the following monoclonal antibodies: CD81FITC, CD22PE, CD3ECD, CD5PercP5.5, CD20PECY7, CD79bAPC, CD38A700, CD43APC Alexa750, CD19eFluor 450, and CD45KO. A modified ISA gating strategy was developed that removed contaminating events. Sensitivity assays were performed using dilution with normal peripheral blood and bone marrow. Clinical samples were compared using the ISA and the single tube assay. Results: Dilution studies showed that sensitivity of 0.001% was achievable when a minimum of 1.8 x 106 total events were acquired. One hundred twenty-nine samples were analyzed and showed RD levels from 0.003 to 22%. In 80 samples analyzed with both assays, there was an excellent correlation between the two methods (slope = 1.0, intercept = 0.07 and R2 = 0.992) and results from BlandAltman analysis showed a bias of 0.04 +/- 0.38 with 95% confidence interval of 0.71 to 0.79. Removal of contaminating events in the single tube assay led to a significant reduction in RD values (P = 0.0014). Conclusion: The single tube 10-color assay for the detection of RD in CLL provides equivalent results to the ISA but requires fewer cells, uses fewer reagents, and allows for simpler analysis. By directly removing contaminating events, it improves the accuracy of CLL RD detection and may reclassify the status of some patients following chemotherapy. (c) 2013 International Clinical Cytometry Society
引用
收藏
页码:96 / 103
页数:8
相关论文
共 50 条
  • [41] Multidimensional flow cytometry for detection of minimal residual disease in acute myeloid leukemia
    Venditti, A
    Maurillo, L
    Buccisano, F
    Tamburini, A
    Del Poeta, G
    Del Principe, MI
    Panetta, P
    Consalvo, MI
    Mazzone, C
    Tendas, A
    Trawinska, M
    Forte, V
    Amadori, S
    LEUKEMIA & LYMPHOMA, 2003, 44 (03) : 445 - 450
  • [42] DETECTION OF MINIMAL RESIDUAL DISEASE IN ACUTE-LEUKEMIA BY FLOW-CYTOMETRY
    VISSER, JWM
    MARTENS, ACM
    HAGENBEEK, A
    ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1986, 468 : 268 - 275
  • [43] Assessing minimal residual disease in chronic lymphocytic leukemia
    Rawstron A.C.
    Hillmen P.
    Current Hematologic Malignancy Reports, 2008, 3 (1) : 47 - 53
  • [44] The Role of Minimal Residual Disease in Chronic Lymphocytic Leukemia
    Al-Sawaf, Othman
    Hallek, Michael
    Fischer, Kirsten
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (02) : 97 - 103
  • [45] Eradication of minimal residual disease in chronic lymphocytic leukemia
    Schweighofer C.D.
    Hallek M.
    Wendtner C.-M.
    Current Hematologic Malignancy Reports, 2008, 3 (1) : 54 - 60
  • [46] Minimal residual disease assessment in chronic lymphocytic leukemia
    Maloum, Karim
    HEMATOLOGIE, 2006, 12 (04): : 274 - 281
  • [47] Recent enhancements of minimal residual disease detection by flow-cytometry in chronic lymphocytic leukemia: a study of the French CLL-MRD group
    Dahmani, Abdelmalek
    Arnoulet, Christine
    Baseggio, Lucile
    Campos, Lydia
    Chatelain, Bernard
    Debliquis, Agathe
    Drenou, Bernard
    Jacob, Marie-Christine
    Legac, Eric
    Le Garff-Tavernier, Magali
    Quiney, Claire
    Robillard, Nelly
    Solly, Francoise
    Ticchioni, Michel
    Cartron, Guillaume
    Dartigeas, Caroline
    Feugier, Pierre
    Leblond, Veronique
    Lepretre, Stephane
    Van den Neste, Eric
    Delfau-Larue, Marie-Helene
    Cymbalista, Florence
    Letestu, Remi
    LEUKEMIA & LYMPHOMA, 2015, 56 : 115 - 116
  • [48] Performance of a novel eight-color flow cytometry panel for measurable residual disease assessment of chronic lymphocytic leukemia
    Chen, Xiao
    Chen, Xia
    Zhao, Sishu
    Shi, Yu
    Zhang, Ninghan
    Guo, Zhen
    Qiao, Chun
    Jin, Huimin
    Zhu, Liying
    Zhu, Huayuan
    Li, Jianyong
    Wu, Yujie
    CYTOMETRY PART B-CLINICAL CYTOMETRY, 2024, 106 (03) : 181 - 191
  • [49] CORRELATION BETWEEN A 10-COLOR FLOW CYTOMETRIC MINIMAL RESIDUAL DISEASE (MRD) ANALYSIS AND MOLECULAR MRD IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA
    Singh, J.
    Gorniak, M.
    Grigoriadis, G.
    Westerman, D.
    McBean, M.
    Venn, N.
    Sutton, R.
    Morgan, S.
    Fleming, S.
    HAEMATOLOGICA, 2017, 102 : 350 - 350
  • [50] Minimal Residual Disease Detection in B-ALL: Comparison of a High-Sensitivity, Single-Tube, 13-Color Flow Cytometry Assay and an NGS-Based Assay
    Liu, Ying
    Gao, Qi
    Mata, Douglas
    Yu, Wayne
    Arcila, Maria
    Nafa, Khedoudja
    Wardrope, Jessica
    Dogan, Ahmet
    Ho, Caleb
    Roshal, Mikhail
    LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 1337 - 1338